Two drugs that have shown success in slowing the progression of Alzheimer’s disease are not available in Canada, which is now the only country in the G7 that has not authorized its use.
It’s leading to growing frustration for patients and care partners who are eager for new treatments.
“I think I either have to wait or go to the (United) States,” said Morley, who was diagnosed with mild Alzheimer’s disease three years ago. “That’s the dilemma we are in.”
Morley learned he had Alzheimer’s accidentally. He got a concussion after a fall while skiing and his wife encouraged him to see a specialist to make sure everything was okay. A PET scan revealed amyloids in his brain, a protein associated with Alzheimer’s, which were unrelated to his concussion.